PRENasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as PRENW
Prenetics Global Ltd
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 30, 2026
$19.02+0.50 (+2.70%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2024
Gross margin
50.3%
Operating margin
-157.2%
Net margin
-151.2%
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +40.8% | +34.7% | – | – | |
| Gross profit | +74.4% | +62.3% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -24.6% | |
| Return on assets | – | – | -19.8% | |
| Current ratio | – | – | 2.36 | |
| Interest coverage | – | – | – | |
| Inventory turnover | – | – | 3.1× | |
| Capex to revenue | – | – | 3.3% | |
| Diluted shares | – | – | 12M |
Where the cash went
Fiscal 2020 to 2024, five years combined
Prenetics Global generated $73.45M from operations and spent $17.71M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$73.45M
Used
$17.71M
Capital expenditure$17.71M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-151.2%
×Asset turnover0.13×
×Equity multiplier1.24×
=Return on equity, FY2024-24.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -151.2% | 0.13× | 1.24× | -24.6% |
| FY2023 | -288.5% | 0.08× | 1.28× | -28.3% |
| FY2022 | -1446.8% | 0.06× | -2.81× | 232.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
4of 8 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero-$46.30M
- Cash generatingOperating cash flow above zero-$28.87M
- Return on assets improvedROA up on the prior year-20.1% → -18.2%
- Earnings backed by cashOperating cash flow above net income-$28.87M vs -$46.30M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.37 → 2.36
- No dilutionShare count did not rise11M → 12M
- Gross margin improvedGross margin up on the prior year40.61% → 50.29%
- More efficientAsset turnover rose0.07 → 0.12